To elucidate whether NfL could be used as a quantitative outcome measure also for onset and progression of the non-inflammatory milder X-ALD variant, we compared the amount of NfL with the severity of the myelopathy in individual AMN patients as determined by the EDSS. This evidence concerns the gene NEFL and adrenoleukodystrophy.